Skip to main navigation
Skip to search
Skip to main content
Mayo Clinic Home
Home
Profiles
Departments/Divisions
Grants
Research output
Prizes
Search by expertise, name or affiliation
Senolytic drugs: from discovery to translation
J. L. Kirkland
,
T. Tchkonia
General Internal Medicine
Physiology & Biomedical Engineering
Research output
:
Contribution to journal
›
Review article
›
peer-review
41
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Senolytic drugs: from discovery to translation'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Clinical Trial
100%
Programmed Cell Death
100%
Frailty
100%
Eye Disease
100%
Diseases
100%
Cardiovascular Disease
50%
Cancer Therapy
50%
Diabetes
50%
Alzheimer's Disease
50%
Silo-Filler's Disease
50%
Cancer
50%
Bone Marrow Transplantation
50%
Sulfhemoglobinemia
50%
Upregulation
50%
Osteoporosis
50%
Liver Disease
50%
Antiapoptotic
50%
Nephropathy
50%
Idiopathic Pulmonary Fibrosis
50%
Organ Transplantation
50%
Childhood Cancer
50%
Osteoarthritis
50%
Multiple Chronic Conditions
50%
Dasatinib
50%
COVID-19
50%
Quercetin
50%
Fisetin
50%
Musculoskeletal Disease
50%
Dermatosis
50%
Navitoclax
50%
Disease
50%
Health Expenditure
50%
Radiation Therapy
50%
Proteans
50%
Keyphrases
Senolytics
100%
Senescent Cells
77%
Clinical Trials
22%
Senescence-associated Secretory Phenotype
22%
Apoptosis
22%
Frailty
22%
Cardiovascular Disease
11%
Radiation Therapy
11%
Diabetes
11%
Morbidity Mortality
11%
Alzheimer's Disease
11%
Age-related
11%
Aging
11%
Inflammation
11%
Bone Marrow Transplantation
11%
Hematological Diseases
11%
Cancer Treatment
11%
Aging Mechanism
11%
Osteoporosis
11%
Liver Disease
11%
Drug Class
11%
Lung Disorders
11%
Kidney Disease
11%
Over 40
11%
Hypothesis-driven Approach
11%
Eye Diseases
11%
Organ Transplantation
11%
Skin Diseases
11%
Childhood Cancer Survivors
11%
Osteoarthritis
11%
Multiple Chronic Conditions
11%
Idiopathic Pulmonary Fibrosis
11%
Dasatinib
11%
Neighboring Cells
11%
Metabolic Disorders
11%
Quercetin
11%
Fisetin
11%
Neuropsychiatric Disorders
11%
Musculoskeletal Disorders
11%
Chronic Disorders
11%
Anti-apoptotic Pathways
11%
Skin Problems
11%
Navitoclax
11%
Hit-and-run
11%
Eye Disorders
11%
Health Expenditure
11%
Disorder Potential
11%
Disease COVID-19
11%